140 related articles for article (PubMed ID: 33062193)
1. Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy.
Dawicki W; Allen KJH; Garg R; Geoghegan EM; Berger MS; Ludwig DL; Dadachova E
Oncotarget; 2020 Sep; 11(39):3571-3581. PubMed ID: 33062193
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive effects of (131)I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models.
Ruffner KL; Martin PJ; Hussell S; Nourigat C; Fisher DR; Bernstein ID; Matthews DC
Cancer Res; 2001 Jul; 61(13):5126-31. PubMed ID: 11431350
[TBL] [Abstract][Full Text] [Related]
3. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG
J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8
Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM; Wrangle JM; Cole DJ; Rubinstein MP
Cancer Res; 2018 Jun; 78(11):3067-3074. PubMed ID: 29636345
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation.
Bethge WA; Wilbur DS; Sandmaier BM
Leuk Lymphoma; 2006 Jul; 47(7):1205-14. PubMed ID: 16923548
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
8. Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.
Fichou N; Gouard S; Maurel C; Barbet J; Ferrer L; Morgenstern A; Bruchertseifer F; Faivre-Chauvet A; Bigot-Corbel E; Davodeau F; Gaschet J; Chérel M
Front Med (Lausanne); 2015; 2():76. PubMed ID: 26582128
[TBL] [Abstract][Full Text] [Related]
9. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.
Nelson MH; Bowers JS; Bailey SR; Diven MA; Fugle CW; Kaiser AD; Wrzesinski C; Liu B; Restifo NP; Paulos CM
J Immunother Cancer; 2016; 4():6. PubMed ID: 26885368
[TBL] [Abstract][Full Text] [Related]
11. Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumours.
Youshani AS; Rowlston S; O'Leary C; Forte G; Parker H; Liao A; Telfer B; Williams K; Kamaly-Asl ID; Bigger BW
J Neuroinflammation; 2019 Feb; 16(1):25. PubMed ID: 30722781
[TBL] [Abstract][Full Text] [Related]
12. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Heczey A; Louis CU; Savoldo B; Dakhova O; Durett A; Grilley B; Liu H; Wu MF; Mei Z; Gee A; Mehta B; Zhang H; Mahmood N; Tashiro H; Heslop HE; Dotti G; Rooney CM; Brenner MK
Mol Ther; 2017 Sep; 25(9):2214-2224. PubMed ID: 28602436
[TBL] [Abstract][Full Text] [Related]
13. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
14. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID
Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324
[TBL] [Abstract][Full Text] [Related]
15. Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.
Ménager J; Gorin JB; Maurel C; Drujont L; Gouard S; Louvet C; Chérel M; Faivre-Chauvet A; Morgenstern A; Bruchertseifer F; Davodeau F; Gaschet J; Guilloux Y
PLoS One; 2015; 10(6):e0130249. PubMed ID: 26098691
[TBL] [Abstract][Full Text] [Related]
16. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
17. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes.
Zhang L; Sosinowski T; Cox AR; Cepeda JR; Sekhar NS; Hartig SM; Miao D; Yu L; Pietropaolo M; Davidson HW
J Autoimmun; 2019 Jan; 96():50-58. PubMed ID: 30122420
[TBL] [Abstract][Full Text] [Related]
19. CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity.
Kueberuwa G; Kalaitsidou M; Cheadle E; Hawkins RE; Gilham DE
Mol Ther Oncolytics; 2018 Mar; 8():41-51. PubMed ID: 29367945
[TBL] [Abstract][Full Text] [Related]
20. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
Gattinoni L; Finkelstein SE; Klebanoff CA; Antony PA; Palmer DC; Spiess PJ; Hwang LN; Yu Z; Wrzesinski C; Heimann DM; Surh CD; Rosenberg SA; Restifo NP
J Exp Med; 2005 Oct; 202(7):907-12. PubMed ID: 16203864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
